UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

 
• By Cathy Kelly
House of mirrors
What does UnitedHealthcare's decision on Neulasta and its biosimilars reflect? That depends on where you stand.

More from Market Access

More from Pink Sheet